Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2007
05/15/2007US7217698 Tetraacylated N-cyclopropylcarbonylmannosamines; treating Alzheimer's and Parkinson's disease
05/15/2007US7217697 Sodium dependent glucose transporter 1 inhibitors; blocking small intestine absorption of glucose; diabetes
05/15/2007US7217696 Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
05/15/2007US7217687 Use of osteopontin for the treatment and/or prevention of neurologic diseases
05/15/2007US7217681 Pesticidal composition and method for fungal control
05/15/2007US7217575 Avidin derivatives and uses thereof
05/15/2007US7217571 The procedure introduces small fragments of exogenous DNA into regions of endogenous genomic DNA virtually homologous to exogenous DNA; ogenous DNA fragments contains sequence modification that correct mutations in endogenous DNA or introduce mutations that alter cellular or infecting pathogen phenotype
05/15/2007US7217569 Clonal cultures of primate embryonic stem cells
05/15/2007US7217555 isolated human NAALAD-ase (N-acetylated alpha-linked acidic dipeptidases) L protein;
05/15/2007US7217535 Immunoassay diagnosis of susceptibility to atherosclerosis by analyzing blood for presence of enzyme using polyclonal or monoclonal antibodies; elevated levels are indicative of susceptibility
05/15/2007US7217534 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
05/15/2007US7217511 Methods of increasing antibiotic production in Streptomyces by deletion of the scbA gene
05/15/2007US7217457 Mixture of hydrophobic polymer core and nanoparticles; immobilization
05/15/2007US7217430 1900 to 2600 mg amoxycillin and an amount of potassium clavulanate such that the weight ratio of amoxycillin to clavulanate is 2:1 to 20:1, at a dosage regiment/interval of about 12 hours; pharmacokinetics; time release
05/15/2007US7217429 Preventing the drug breakdown due to abnormal secretion of gastric acid, coatings comprising non-alkaline water-soluble cellulose such as hydroxypropylmethyl cellulose or hydroxypropyl cellulose
05/15/2007US7217428 For controlled release of compounds through the use of a chemically sensitive cantilever
05/15/2007US7217422 Compositions and methods for enhancing corticosteroid delivery
05/15/2007US7217417 Gel-based cosmetic and wound-healing formulation and method
05/15/2007US7217415 NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use
05/15/2007CA2437844C Method for increasing leptin levels using nicotinic acid compounds
05/15/2007CA2399709C Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
05/15/2007CA2392973C Benzoimidazole derivatives useful as antiproliferative agents
05/15/2007CA2374767C Optically active quinoline carboxylic acid derivatives having 7-pyrrolidine substitutes causing optical activity and a process for preparing thereof
05/15/2007CA2366829C Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
05/15/2007CA2366186C Retinoid antagonists and use thereof
05/15/2007CA2325739C Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
05/15/2007CA2295087C Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
05/15/2007CA2294337C Preparation of pharmaceutical compositions
05/15/2007CA2281944C Methods and compositions for preventing and treating chronological aging in human skin
05/15/2007CA2268455C Methods and apparatus for treatment of parkinson's disease
05/15/2007CA2266811C Method and composition for wound treatment
05/15/2007CA2255540C Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
05/15/2007CA2215258C Method of making a pressure sensitive skin adhesive sheet material
05/15/2007CA2159822C Process for inhibiting the transcription of genes
05/15/2007CA2155275C Aminoalkyloximes, a process for their preparation, their use as medicaments and intermediate compounds
05/15/2007CA2134961C Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses
05/15/2007CA2127445C Nutrient composition
05/10/2007WO2007053847A2 Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
05/10/2007WO2007053846A1 Compositions of hoodia gordonii and pinolenic acid derivatives
05/10/2007WO2007053844A2 Compositions and methods for treating inflammatory disorders
05/10/2007WO2007053819A2 Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
05/10/2007WO2007053810A2 Liposomally encapsulated reduced glutathione, including with other pharmacologic preparation, capable of administration as an oral, topical, intraoral or transmucosal, preparation, for reversal and prevention of oxidation of cholesterol and of low density lipoprotein
05/10/2007WO2007053807A2 Calcitriol for treating intraocular diseases associated with angiogenesis
05/10/2007WO2007053796A2 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
05/10/2007WO2007053776A1 Pyrimidinyl-thiophene kinase modulators
05/10/2007WO2007053773A1 Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia and cardiovascular disease
05/10/2007WO2007053757A2 Flavanols and b-type procyanidins and inflammation
05/10/2007WO2007053747A2 Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
05/10/2007WO2007053729A2 High load particles for inhalation having rapid release properties
05/10/2007WO2007053725A2 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
05/10/2007WO2007053724A2 Crystalline forms of cefdinir potassium salt
05/10/2007WO2007053700A2 Use of pyridoxamine to treat and/or prevent disease processes
05/10/2007WO2007053698A2 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
05/10/2007WO2007053685A2 Methods of treating atrial fibrillation with p38 inhibitor compounds
05/10/2007WO2007053684A2 Neuroprotective agents
05/10/2007WO2007053662A1 Dihydroisoindolones as allosteric modulators of glucokinase
05/10/2007WO2007053658A1 Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf)
05/10/2007WO2007053657A1 Substituted pyrrolones as allosteric modulators of glucokinase
05/10/2007WO2007053650A2 Diazonamide a analog
05/10/2007WO2007053642A1 Flavanols and b-type procyanidins and cox-2 expression
05/10/2007WO2007053641A2 A-type procyanidins and inflammation
05/10/2007WO2007053639A2 A-type procyanidins and cox-2 expression
05/10/2007WO2007053622A2 Methods for modulating ppar activity to treat diseases caused by mutations in the cftr gene
05/10/2007WO2007053618A1 Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
05/10/2007WO2007053610A2 Methods of treating atrial fibrillation wtih pirfenidone
05/10/2007WO2007053596A1 Gaba receptor mediated modulation of neurogenesis
05/10/2007WO2007053580A2 Sigma ligands for neuronal regeneration and functional recovery
05/10/2007WO2007053574A2 Combinations comprising sorafenib and interferon for the treatment of cancer
05/10/2007WO2007053573A2 Treatment of cancer with sorafenib
05/10/2007WO2007053526A1 Compositions and methods for identifying modulators of trpv2
05/10/2007WO2007053514A2 Chemical preconditioning as a preventative or treatment for excitotoxic synaptic damage
05/10/2007WO2007053506A1 Aspartyl protease inhibitors
05/10/2007WO2007053503A1 Substituted dihydroisoindolones as allosteric modulators of glucokinase
05/10/2007WO2007053499A2 Compounds useful as antagonists of ccr2
05/10/2007WO2007053498A1 Compounds useful as antagonists of ccr2
05/10/2007WO2007053495A2 Compounds useful as antagonists of ccr2
05/10/2007WO2007053452A1 Bi-aryl meta-pyrimidine inhibitors of kinases
05/10/2007WO2007053447A2 Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions
05/10/2007WO2007053435A1 3 -monosubstituted tropane derivatives as nociceptin receptor ligands
05/10/2007WO2007053422A1 User-adjustable treatment methods, systems and compositions for treating acne
05/10/2007WO2007053400A2 Piperidine glycine transporter inhibitors
05/10/2007WO2007053394A1 Kinase inhibitors
05/10/2007WO2007053393A2 Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
05/10/2007WO2007053392A2 Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
05/10/2007WO2007053384A1 Dispensing brush with replaceable cartridge/handle part
05/10/2007WO2007053353A2 Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
05/10/2007WO2007053346A1 Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
05/10/2007WO2007053345A1 Glucokinase activators
05/10/2007WO2007053284A2 Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor
05/10/2007WO2007053271A2 In vitro and in vivo anti-inflammatory effects of a sesquiterpene lactone extract from chicory (cichorium intybus l.)
05/10/2007WO2007053193A2 Unsolvated benzodiazepine compositions and methods
05/10/2007WO2007053145A1 Haloperidol analogs
05/10/2007WO2007053134A1 A method for normalizing insulin levels
05/10/2007WO2007053131A2 Acrylamide derivatives as antibiotic agents
05/10/2007WO2007053095A1 Chroman compounds as 5-ht1b antagonists
05/10/2007WO2007053094A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS
05/10/2007WO2007053093A1 Chroman compounds as 5 ht1b antagonists
05/10/2007WO2007053082A1 Novel 1 -benzyl-4-piperidinamines that are useful in the treatment of copd and asthma
05/10/2007WO2007052999A1 Pharmaceutical compositions combining analgesics and anticonvulsant agents for the treatment of chronic and acute pain
05/10/2007WO2007052943A1 Novel antifungal triazole derivatives
1 ... 3757 3758 3759 3760 3761 3762 3763 3764 3765 3766 3767 3768 3769 3770 3771 3772 3773 3774 3775 3776 3777 ... 7860